Company intelligence / Profile preview

Vestan

Ownership: Private
Development stage: Preclinical

Overview

Vestan Ltd. is developing VST‑1001, a dilute formulation of fluorescein sodium, as an intraoperative imaging agent to assist surgeons with sentinel lymph node biopsy procedures in patients with clinically node-negative breast cancer. The company sponsored at least one Phase I/II clinical trial to determine optimal dosing and efficacy when used alongside standard radiotracers during surgery. No published results or approvals are noted as of March 2025; the latest available status lists the trial as "unknown".

Therapeutic areas: Oncology
Modalities: Small moleculeDiagnostic agent
Industry: Metabolite Diagnostics

Beyond the preview

Go deeper on Vestan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vestan.

Explore the full profile